Abstract
Mass spectrometry plays an increasingly important role in the search for and quantification of novel chemically specific biomarkers. The revolutionary advances in mass spectrometry instrumentation and technology empower scientists to specifically analyze DNA and protein adducts, considered as molecular dosimeters, derived from reactions of a carcinogen or its active metabolites with DNA or protein. Analysis of the adducted DNA bases and proteins can elucidate the chemically reactive species of carcinogens in humans and can serve as risk‐associated biomarkers for early prediction of cancer risk. In this article, we review and compare the specificity, sensitivity, resolution, and ease‐of‐use of mass spectrometry methods developed to analyze ethylene oxide (EO)‐induced DNA and protein adducts, particularly N7‐(2‐hydroxyethyl)guanine (N7‐HEG) and N‐(2‐hydroxyethyl)valine (HEV), in human samples and in animal tissues. GC/ECNCI‐MS analysis after HPLC cleanup is the most sensitive method for quantification of N7‐HEG, but limited by the tedious sample preparation procedures. Excellent sensitivity and specificity in analysis of N7‐HEG can be achieved by LC/MS/MS analysis if the mobile phase, the inlet (split or splitless), and the collision energy are properly optimized. GC/ECNCI‐HRMS and GC/ECNCI‐MS/MS analysis of HEV achieves the best performance as compared with GC/ECNCI‐MS and GC/EI‐MS. In conclusion, future improvements in high‐throughput capabilities, detection sensitivity, and resolution of mass spectrometry will attract more scientists to identify and/or quantify novel molecular dosimeters or profiles of these biomarkers in toxicological and/or epidemiological studies. © 2011 Wiley Periodicals, Inc., Mass Spec Rev 30:733–756, 2011